Finally, the expression levels of PRKCB and SRD5A2 were validated in prostate cancer and adjacent normal tissues using clinical samples.<h4>Conclusion</h4>PRKCB and SRD5A2 were identified as potential immunological biomarkers and immunotherapeutic targets associated with immune cell infiltration in PCa, both of which were significantly downregulated in PCa tissues. The gene discussed is PRKCB; the disease is Familial prostate cancer.